Any feedback?
Please rate this page
(all_enzymes.php)
(0/150)

BRENDA support

2.7.1.3: ketohexokinase

This is an abbreviated version!
For detailed information about ketohexokinase, go to the full flat file.

Word Map on EC 2.7.1.3

Reaction

ATP
+
D-fructose
=
ADP
 +
D-Fructose 1-phosphate

Synonyms

ATP:D-fructose 1-phosphotransferase, fructokinase, ketohexokinase, ketohexokinase (phosphorylating), KHK, Khk-A, Khk-C

ECTree

     2 Transferases
         2.7 Transferring phosphorus-containing groups
             2.7.1 Phosphotransferases with an alcohol group as acceptor
                2.7.1.3 ketohexokinase

Disease

topprint

Disease on EC 2.7.1.3 - ketohexokinase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Carcinogenesis
Prognostic Impact of Metabolism Reprogramming Markers Acetyl-CoA Synthetase 2 Phosphorylation and Ketohexokinase-A Expression in Non-Small-Cell Lung Carcinoma.
Carcinoma
KHK-A promotes the proliferation of oesophageal squamous cell carcinoma through the up-regulation of PRPS1.
The expression of ketohexokinase is diminished in human clear cell type of renal cell carcinoma.
Carcinoma, Hepatocellular
A splicing switch from ketohexokinase-C to ketohexokinase-A drives hepatocellular carcinoma formation.
Carcinoma, Renal Cell
The expression of ketohexokinase is diminished in human clear cell type of renal cell carcinoma.
Cardiomegaly
HIF-driven SF3B1 induces KHK-C to enforce fructolysis and heart disease.
Diabetes Mellitus
Endogenous fructose is correlated with urinary albumin creatinine ratios and uric acid in type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Endogenous fructose is correlated with urinary albumin creatinine ratios and uric acid in type 2 diabetes mellitus.
Esophageal Squamous Cell Carcinoma
KHK-A promotes the proliferation of oesophageal squamous cell carcinoma through the up-regulation of PRPS1.
Fatty Liver
Divergent effects of glucose and fructose on hepatic lipogenesis and insulin signaling.
Ketohexokinase inhibition improves NASH by reducing fructose-induced steatosis and fibrogenesis.
Fructose Intolerance
Expression of rat liver ketohexokinase in yeast results in fructose intolerance.
Glioma
Ketohexokinase is involved in fructose utilization and promotes tumor progression in glioma.
Heart Diseases
HIF-driven SF3B1 induces KHK-C to enforce fructolysis and heart disease.
Hepatitis
Science letters: Proteomic analysis of differentially expressed proteins in mice with concanavalin A-induced hepatitis.
Hyperoxaluria
Calciuria, oxaluria and phosphaturia after ingestion of glucose, xylitol and sorbitol in two population groups with different stone-risk profiles.
Hypoglycemia
Ketohexokinase C blockade ameliorates fructose-induced metabolic dysfunction in fructose-sensitive mice.
Insulin Resistance
Fructose and hepatic insulin resistance.
ketohexokinase deficiency
Properties of normal and mutant recombinant human ketohexokinases and implications for the pathogenesis of essential fructosuria.
Tissue-Specific Fructose Metabolism in Obesity and Diabetes.
Liver Diseases
Fructose and fructose kinase in cancer and other pathologies.
Ketohexokinase inhibition improves NASH by reducing fructose-induced steatosis and fibrogenesis.
Metabolic Syndrome
Short-term fructose ingestion affects the brain independently from establishment of metabolic syndrome.
Neoplasms
Dietary fructose improves intestinal cell survival and nutrient absorption.
Fructose and fructose kinase in cancer and other pathologies.
Ketohexokinase is involved in fructose utilization and promotes tumor progression in glioma.
KHK-A promotes the proliferation of oesophageal squamous cell carcinoma through the up-regulation of PRPS1.
Prognostic Impact of Metabolism Reprogramming Markers Acetyl-CoA Synthetase 2 Phosphorylation and Ketohexokinase-A Expression in Non-Small-Cell Lung Carcinoma.
The expression of ketohexokinase is diminished in human clear cell type of renal cell carcinoma.
Non-alcoholic Fatty Liver Disease
Ketohexokinase inhibition improves NASH by reducing fructose-induced steatosis and fibrogenesis.
Obesity
Inhibitors of Ketohexokinase: Discovery of Pyrimidinopyrimidines with Specific Substitution that Complements the ATP-Binding Site.
Pyrimidinopyrimidine inhibitors of ketohexokinase: Exploring the ring C2 group that interacts with Asp-27B in the ligand binding pocket.
Proteinuria
IL-6/STAT3 signaling activation exacerbates high fructose-induced podocyte hypertrophy by ketohexokinase-A-mediated tristetraprolin down-regulation.